PRKCQ-AS1 drives tamoxifen resistance in ER + breast cancer by upregulating MKP1 expression and reducing tamoxifen-induced apoptosis through serving as a molecular sponge of miR-200a-3p. Here, PRKCQ is linked to breast carcinoma.